September 2, 2010
| Bio-IT World > Drug Discovery

Drug Discovery

Loading...

Change page: < >  |  Displaying page 1 of 95, items 1 to 10 of 947.

Roche and IBM Partner to Develop Nanopore Next-Gen Sequencing System

Bio-IT World | Roche is partnering with IBM to develop and market a promising third-generation sequencing technology based on synthetic nanopores. The technology could be commercially released in a five-year timeline, says 454 Life Sciences CEO Chris McLeod.

Craig Venter, Jim Watson, and Ozzy Osbourne?

St. Louis Post-Dispatch | Ozzy Osbourne is having his genome sequenced. St. Louis-based Cofactor Genomics, in conjunction with Knome and Applied Biosystems, will map Ozzy's DNA to try to figure out how he's survived his notorious lifestyle.

Emerald, FORMA Sign Design Partnership

Boston Globe | Emerald BioStructures and FORMA Therapeutics have signed a strategic partnership for structure-based design of cancer drug candidates.

Happy Anniversary, Genome

Reuters | Ten years ago tomorrow, President Clinton announced the first draft of the  human genome. Ten years later, NIH director Francis Collins says that most people have not had the experience of having their personal medical care directly affected by genome sequencing

Cloudera to Connect Oracle and Hadoop

cnet news | Cloudera and Quest Software are announcing a partnership this week to develop, support, and distribute an Oracle connector for Hadoop

We Can't Handle the Truth?

Huffington Post | Wired editor calls the recent FDA ruling on personalized genomics kits evidence of a "stubborn paternalistic streak in our healthcare system." 

OSDD Results to be Peer Reviewed, Say Researchers

Nature News | Nature News has issued a correction to a story it published on June 9 stating that Open Source Drug Discovery (OSDD) did not plan to publish its Mycobacterium tuberculosis genome in a peer-reviewed journal.

Early Trial Planning Solutions

Bio-IT World | Medidata announced two new products at the Drug Information Association (DIA) meeting this week in Washington, D.C.: an updated version of Grants Manager and Medidata Balance.

Australia Buys the World’s Largest Life Sciences Supercomputer

Bio-IT World | The Victoria Life Sciences Computation Initiative (VLSCI) in Victoria, Australia, has announced that it will have the world’s largest life sciences-dedicated supercomputer by 2012. The purchased IBM Blue Gene machine is expected to have around 64,000 cores.

FDA Requires Review of Personal Genomics Kits

San Francisco Chronicle | The FDA sent letters to 23andMe, Navigenics, deCODE Genetics, Illumina, and Knome on Friday explaining that the companies' consumer genomics kits should be reviewed by the agency.



White Papers & Special Reports

oracle_RDC
Remote Data Capture:Acquisition and Analysis
Sponsored by Oracle

See why Electronic Data Capture (EDC) is gaining traction in the pharmaceutical
clinical trials arena. Today approximately half of all clinical trials are conducted
electronically, and the figure is rapidly rising. Report includes contributions from
Oracle Health Sciences, Pfizer, PPD, and C3i.

 



oracle20723
The Role of Analytics in Transforming Healthcare
Sponsored by Oracle

Sharing many of the data challenges and opportunities faced by Healthcare, the Life Sciences industry remains focused on delivering new, innovative therapies and solutions to patients in a cost effective, timely and safe way. With spiraling R&D costs, new methods such as adaptive trials, and never ending need for deep pharmacovigilance, the Life Sciences companies that effectively use analytics to explore, monitor and optimize their business will rapidly become the new leaders.

Oracle’s strategy—built upon Enterprise Health Analytics and Health Data Warehouse Foundation—provides a powerful, practical, and extensible approach to delivering the IT analytics infrastructure required to confront the worldwide healthcare challenge.



pegasystems
BPM-Based Case Management Approach to Optimizing Clinical Trial Efficiency
Sponsored by Pegasystems

Business Process Management (BPM) software offers liberation in the planning and management of clinical trials today. SmartBPM provides the components for automating critical clinical trial processes ranging from protocol development and patient enrollment to site management and investigator payments. Advantages are:

  • Potentially stunning return on investment at multiple levels.
  • A 500%, or better, increase in application development time by directly executing business requirements
  • Improved customer retention
  • A 50% possible reduction in training time

Discovered is opportunity to enhance relationships with investigators, subjects, and regulators while bringing momentum to a technology-impaired study startup phase. Learn more about SmartBPM in this complimentary white paper.



Job Openings

mskc logo
Software Engineer – Computational Biology Center

Memorial Sloan-Kettering Cancer Center seeks an Engineer to design and develop complex data analysis systems in support of cancer genomics research projects at the Computational Biology Center. Qualified candidate will have a BA, 5+ years of software development experience and expert knowledge of Java, SQL, and HTML.

Apply: www.mskcciscareers.org.  Equal opportunity and affirmative action employer.

Web Symposia
Loading...

Bio-IT World proudly presents the Bio-IT World Web Symposia Series!

Covering a broad array of topics within the life sciences and drug development industries, these complimentary 90-minute web symposiums provide an interactive platform to learn more about cutting-edge bio-IT topics through expert analysis and discussions.

Leveraging BPM to Increase Efficiencies in Clinical Trial Case Management
Recorded on August 3, 2010
Sponsored by: Pegasystems
Program Details | Access Recording 

Next Gen Data Management for Next Gen Life Sciences
September 8, 2010 | 1:00pm - 2:30pm EST
Sponsored by Quantum
Program Details | Register Today 

 





Loading...

For reprints and/or copyright permission, please contact The YGS Group, 3650 West Market Street, York, PA;

(717) 505-9701 ext. 125, or via email to Ashley.Zander@theYGSgroup.com.